Aptose Biosciences Inc. (TSX:APS)

Market Cap	6.00M
Revenue (ttm)	n/a
Net Income (ttm)	-36.59M
Shares Out	2.14M
EPS (ttm)	-52.35
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,584
Average Volume	8,627
Open	3.100
Previous Close	2.800
Day's Range	2.900 - 3.100
52-Week Range	0.160 - 5.800
Beta	1.21
RSI	45.33
Earnings Date	Mar 27, 2025

About Aptose Biosciences

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company’s clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, wh...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 13
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: APS

Financial Performance

Financial numbers in USD